Earnings summaries and quarterly performance for Anebulo Pharmaceuticals.
Executive leadership at Anebulo Pharmaceuticals.
Board of directors at Anebulo Pharmaceuticals.
Research analysts covering Anebulo Pharmaceuticals.
Recent press releases and 8-K filings for ANEB.
Anebulo Pharmaceuticals Reports Q1 Fiscal Year 2026 Results and Business Updates
ANEB
Earnings
New Projects/Investments
M&A
- Anebulo Pharmaceuticals reported a net loss of $2.2 million, or $(0.05) per share, for the first quarter of fiscal year 2026, which ended September 30, 2025.
- As of September 30, 2025, the company had $10.4 million in cash and cash equivalents, with access to an additional $3.0 million through a Loan Agreement.
- On September 25, 2025, Anebulo announced the dosing of the first subjects in a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of selonabant for acute cannabis-induced toxicity in children. This study is supported by a $994,300 grant from the National Institute on Drug Abuse (NIDA).
- The Board is reviewing strategic alternatives, including a proposed reverse stock split as part of a going private transaction, with a further announcement expected by the end of the year.
Nov 13, 2025, 9:15 PM
Anebulo Pharmaceuticals Reports Q4 and FY 2025 Results, Initiates Clinical Study, and Proposes Reverse Stock Split
ANEB
Earnings
New Projects/Investments
Delisting/Listing Issues
- Anebulo Pharmaceuticals reported a net loss of $2.1 million, or $(0.05) per share, for the fourth quarter of fiscal year 2025, and a net loss of $8.5 million, or $(0.25) per share, for the full fiscal year 2025.
- As of June 30, 2025, the company had $11.6 million in cash and cash equivalents.
- On September 25, 2025, Anebulo initiated a Phase 1 single ascending dose (SAD) study for an intravenous (IV) formulation of its lead drug candidate, selonabant, for acute cannabis-induced toxicity in children, supported by a $994,300 grant from the National Institute on Drug Abuse (NIDA).
- The Board of Directors has approved a proposed reverse stock split, subject to stockholder approval, as part of a going private transaction intended to maintain fewer than 300 record holders and avoid SEC public reporting requirements.
Sep 29, 2025, 8:15 PM
Quarterly earnings call transcripts for Anebulo Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Anebulo Pharmaceuticals's earnings for you
Get instant analysis when filings drop